Please find the information below.
Generally it is same the only difference being the country of concern.
SPCs were formed by a new
regulation that came into
effect on January 2 1993
in nine of the European
Union countries -
Belgium, Denmark, France,
Germany, Ireland, Italy,
Luxembourg, the
Netherlands and the UK.
SPCs were not allowed in
Spain, Greece or Portugal
until January 1998.
From 1994 onwards, those
EFTA (European Free Trade
Association) countries
which were party to the
European Economic Area
Agreement (Austria,
Finland, Iceland, Norway
and Sweden) adopted the
EC regulations.
Liechtenstein came into
the ring under the EFTA
agreement.
An SPC lasts for up to a
maximum of five years and
was designed to provide
for up to a maximum of 15
years monopoly on
marketed drugs. The SPC
is not an automatic right
and has to be applied for
in each individual state.
The SPC duration allowed
cannot exceed five years.
To calculate the SPC
period allowable you take
the time difference
between the patent
application date and the
date of the first
marketing approval in the
first EU State and
subtract five years. If
this is greater than five
years the SPC period is
restricted to the maximum
five-year term. If a
patent was applied for
five years or less before
the first marketing
approval then the SPC
period is zero
"D M Acharya"
<dmacharya@alemb To: <piug-l@derwent.co.uk>
ic.co.in> cc:
Sent by: Subject:
owner-piug-l@der
went.co.uk
07/25/02 11:06
AM
I have come across the terminology CCP (Complementary Protection
certificate). I would like to know how it is given & is it different from
SPC or it incorporated with SPC.
Best Regards,
d.m.Acharya
Alembic Ltd
Alembic Road
Baroda-390 003
India
----------------------------------------------------------------------------------------------------------------------
The information contained in this email is confidential and intended
only for the use of the individual or entity named above. If the reader
of this message is not the intended recipient, you are hereby notified
that any dissemination, distribution, or copying of this communication
is strictly prohibited. Derwent Information Limited will accept no
responsibility
or liability in respect to this email other than to the addressee. If you
have received this communication in error, please notify us
immediately via email: postmaster@derwent.co.uk
----------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------
The information contained in this email is confidential and intended
only for the use of the individual or entity named above. If the reader
of this message is not the intended recipient, you are hereby notified
that any dissemination, distribution, or copying of this communication
is strictly prohibited. Derwent Information Limited will accept no
responsibility
or liability in respect to this email other than to the addressee. If you
have received this communication in error, please notify us
immediately via email: postmaster@derwent.co.uk
----------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------
The information contained in this email is confidential and intended
only for the use of the individual or entity named above. If the reader
of this message is not the intended recipient, you are hereby notified
that any dissemination, distribution, or copying of this communication
is strictly prohibited. Derwent Information Limited will accept no responsibility
or liability in respect to this email other than to the addressee. If you
have received this communication in error, please notify us
immediately via email: postmaster@derwent.co.uk
----------------------------------------------------------------------------------------------------------------------
This archive was generated by hypermail 2b30 : Fri Feb 14 2003 - 11:56:56 GMT